The GHG protocol categorizes emissions into three scopes: Scope 1 for direct emissions, Scope 2 for indirect emissions from purchased electricity, and Scope 3 for other indirect emissions.

For pharmaceutical companies, Scope 3 emissions often make up over 90% of the total, presenting a significant challenge for direct action.

However, addressing Scope 1 and Scope 2 emissions can have a ripple effect, positively impacting Scope 3 emissions throughout the supply chain.

Our experts explain, through the following article, the engineering solutions studied and applied for a recent case study of a new biotech pharmaceutical facility.

Read the article to discover the implemented actions and their impact in terms of emissions reduction.